Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday

The mean of analysts' price targets for Exact Sciences (EXAS) points to a 34.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Exact Sciences (EXAS) Could Rally 34.33%: Here's is How to Trade

Exact Sciences Corporation (NASDAQ:EXAS ) Wells Fargo 2024 Healthcare Conference September 5, 2024 3:45 PM ET Company Participants Aaron Bloomer - Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Brandon Couillard Alright, folks. We'll go ahead and get started.

Exact Sciences Corporation (EXAS) at Wells Fargo 2024 Healthcare Conference - Transcript

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

Exact Sciences (EXAS) Up 7.5% Since Last Earnings Report: Can It Continue?

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Wells Fargo Healthcare Conference, Boston Fireside chat on Wednesday, September 4, 2024 at 3:45 p.m. ET Baird Global Healthcare Conference, New York Fireside chat on Wednesday, September 11, 2024 at 10:15 a.m. ET The webcasts can be a.

Exact Sciences to Participate in September Investor Conferences

The average of price targets set by Wall Street analysts indicates a potential upside of 34.1% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Exact Sciences (EXAS) Have the Potential to Rally 34.13% as Wall Street Analysts Expect?

Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.

Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches

Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.

Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the first patient has joined its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence (RWE) study at Baylor Scott & White, the primary study site and largest not-for-profit health system in Texas. The multi-site study will enroll up to 25,000 patients, evaluating the clinical performance, patient and provider experience, an.

Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study

Exact Sciences stock is down 35% since August 2021, now trading at around $58.75. The second quarter of 2024 (Q2) results beat expectations with revenue growth driven by the Cologuard screening segment. It raised adjusted EBITDA guidance for 2024, demonstrating confidence in continued sales momentum and profitability.

Exact Sciences: Cost Optimization And Product Strength

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, shared new modeling data today describing the projected impact of the Cologuard test on patients, health care professionals, and the U.S. health care system since its FDA approval 10 years ago. The data assessed the far-reaching benefits of the first and only multi-target stool DNA test for patients, their families, and the health care system. Over the past 10 years,.

New Modeling Data Show the Cologuard® Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion

Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.

Why You Should Add Exact Sciences (EXAS) to Your Portfolio

The consensus price target hints at a 45% upside potential for Exact Sciences (EXAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 45.04% Upside in Exact Sciences (EXAS): Here's What You Should Know

Exact Sciences Corporation EXAS reported better-than-expected second-quarter financial results on Wednesday.

Exact Sciences Analysts Slash Their Forecasts After Q2 Results

Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.

Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat

Exact Sciences stock bounded higher Thursday after beating second-quarter expectations, signaling a return to growth for Cologuard.

Why Exact Sciences, Up 20%, Is 'Coiled To Snap Back' After Quarterly Beat

Exact Sciences (EXAS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago.

Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates

Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Erik Holznecht - Manager, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Tycho Peterson - Jefferies Andrew Brackman - William Blair Catherine Schulte - Baird Matt Sykes - Goldman Sachs Dan Arias - Stifel Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Jack Meehan - Nephron Research Michael Ryskin - Bank of America Puneet Souda - Leerink Partners Subbu Nambi - Guggenheim Operator Thank you for standing by. At this time, I would like to welcome everyone to today's Exact Sciences Second Quarter 2024 Earnings Call.

Exact Sciences Corporation (EXAS) Q2 2024 Earnings Call Transcript

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $699 million for the second quarter ended June 30, 2024, compared to $622 million for the same period of 2023. “Our second quarter results show the dedication of Exact Sciences' world-class team and the power of our unique platform,” said Kevin Conroy, chairman and CEO. “We delivered answers to more patients and h.

Exact Sciences Announces Second-Quarter 2024 Results

24/7 Wall Street Insights Early cancer detection is the first line of defense in preventing the disease's progression and reducing fatalities.

The Single Best Stock to Buy Under $50

ST. LOUIS--(BUSINESS WIRE)--U.S. PTAB instituted inter partes review based on Geneoscopy's challenge against the validity of Patent '781 owned by Exact Sciences.

U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy's Petition Challenging Validity of ‘781 Patent Owned by Exact Sciences

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Amazon

Snowflake

More than halfway through the year and the stock market is not done setting new all-time highs. With inflation ticking lower for the first time in four years possibly paving the way for interest rate cuts to arrive sooner than expected, investors are bidding up shares.

Goldman Sachs Says Buy These 3 Stocks for Double-Digit Returns

Sarepta Therapeutics

United Therapeutics

In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.

3 Biotech Stocks You Should Know About

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced today that it awarded a total of $1.5 million to 28 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program. Grant recipients are committed to improving colorectal cancer (CRC) screening rates and making health care more accessible, with a focus on medically underserved populations. CRC is one of the most preventable and treatable can.

News for Exact Sciences Stock (EXAS)